The stock of Bluejay Diagnostics Inc. (NASDAQ:BJDX) increased by $1.25 on Wednesday to $4.35, up 40.43 percent. The last five days have seen an average of 6,378,638 shares of common stock traded. 10 times new highs were reached in the current year, with a fall of -$3.17. The average number of shares traded over the last 20 days was 1,653,474, while the average volume over the last 50 days totaled 1,348,992.
BJDX stock dropped -41.72% since last month. On 09/19/23, the company’s shares reached a one-month low of $2.90. The stock touched a high of $18.91 on 02/16/23, after rallying from a low of $2.90 in 52 weeks. The price of BJDX stock has declined by -42.71% or -$3.17 this year, reaching a new high 10 times. Still, the stock price is down -76.98% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended June 29, Bluejay Diagnostics Inc.’s current ratio was 3.60. Based on annual data, it had gross profit of $49000.0 and revenue of $0.25 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BJDX’s return on assets (ROA) during the last 12 months has been -88.10%. There was a -83.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -104.70%.
Earnings Surprise
According to Bluejay Diagnostics Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that Bluejay Diagnostics Inc.’s quarterly earnings would be -$2.75, but it ended up being -$1.5, beating the consensus by -83.30%. EBITDA was -$2.61 million for the quarter. At the end of Bluejay Diagnostics Inc.’s most recent quarter ended June 29, its liabilities totaled 2.1 million, while its total debt was $0.44 million. Equity owned by shareholders amounts to $1.02 million.
Technical Picture
Here’s a quick look at Bluejay Diagnostics Inc.’s (BJDX) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 49.09%, suggesting the stock is Neutral, with a 209.41% historical volatility rate.
The stochastic %K and %D were 17.32% and 8.48% respectively, while the average true range (ATR) was 0.84. Based on the 14-day stochastic reading of 41.56%, the RSI (14) reading is 44.19%. On the 9-day MACD Oscillator, the stock is at -0.13, and the 14-day reading is at -0.65.
Analyst Ratings
Analysts have assigned Bluejay Diagnostics Inc. (BJDX) an Hold rating. BJDX is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is BJDX’s price target for the next 12 months?
The current consensus forecast for the stock is between $32.00 and $32.00, with a median target price of $32.00. In analyzing these forecasts, the average price target given by analysts for Bluejay Diagnostics Inc. (BJDX) is $32.00.
